7.11. guidelines treatment tat1 tumours carcinoma situ according risk stratification. recommendationsstrength ratingeau risk group: lowoffer one immediate instillation intravesical chemotherapy transurethral resection bladder (turb).strongeau risk group: intermediatein general, chemotherapy (the optimal schedule unknown) reasonable first-line option majority patients. one-year full-dose bcg treatment (induction plus three-weekly instillations 3, 6 12 months), alternative option. final choice reflect individual patient’s risk recurrence progression well efficacy side effects treatment modality. offer one immediate chemotherapy instillation patients small papillary recurrences detected one year previous turb.strongeau risk group: highoffer intravesical full-dose bcg instillations one three years discuss immediate radical cystectomy (rc).strongeau risk group: highoffer rc intravesical full-dose bcg instillations one three years, particularly decline unfit rc.strong table 7.3: treatment options various categories bcg failure categorytreatment optionsbcg-unresponsive1. radical cystectomy (rc).2. enrolment clinical trials assessing new treatment strategies.3. bladder-preserving strategies patients unsuitable refusing rc.late bcg relapsing:tat1 hg recurrence> 6 months cis> 12 months last bcg exposure1. radical cystectomy repeat bcg course according patient’s individual situation.2. bladder-preserving strategies.3. enrolment clinical trials assessing new treatment strategies.lg recurrence bcg primary intermediate-risk tumour1. repeat bcg intravesical chemotherapy.2. enrolment clinical trials assessing new treatment strategies.